PGT-A Testing: The Evidence Debate, Both Sides

No purchase in IVF is argued about more than PGT-A — preimplantation genetic testing for aneuploidy, the $3,000–6,000 embryo-screening add-on that half the field describes as rational selection and the other half as an expensive way to discard potential. Both camps include serious scientists; both cite real data. This is the debate laid out honestly, both sides at full strength — with this site's standing scope note upfront: PGT here means screening embryos for chromosomal abnormalities and serious genetic disease, and nothing else.

The Mechanism — and Why It Sounds Airtight

Aneuploidy — the wrong number of chromosomes — is the dominant reason embryos fail: it drives most implantation failures and the majority of first-trimester miscarriages, and its rate climbs steeply with maternal age, from a minority of embryos in the early 30s to most of them by the mid-40s. PGT-A biopsies a few trophectoderm cells from each blastocyst, sequences them, and labels embryos euploid (normal count), aneuploid, or mosaic (mixed). Transfer only euploid embryos, the logic runs, and you skip the failures and miscarriages the aneuploid ones guaranteed. The case for testing follows cleanly: fewer failed transfers (don't spend $2,000 FET fees and two-week waits on embryos that couldn't work), fewer miscarriages (with their physical and emotional toll and their months of lost time), faster time to success for patients with several embryos to rank, and information — a couple with five embryos and zero euploids learns something brutal but decision-relevant about next steps. For older patients, where aneuploidy rates are highest, every element of that case strengthens arithmetically.

The Case Against — Why the Trials Keep Disappointing

The skeptics' argument starts with the endpoint this site always starts with: live birth. The landmark randomized STAR trial found no overall improvement in live-birth rates with PGT-A in a general IVF population — and subsequent trials and meta-analyses have repeatedly failed to find the across-the-board benefit the mechanism promises. The explanations are structural, not technicalities. Selection can't create embryos: testing reorders the transfer queue; it adds no viable embryo to the cohort, so cumulative per-retrieval odds — the statistic that matters — can't rise by testing alone. The biopsy and the label carry costs: a trophectoderm sample may not represent the whole embryo — mosaicism means some "abnormal" results belong to embryos that self-correct or were mislabeled, and the non-selection studies (where flagged embryos were transferred anyway) documented healthy births from embryos testing would have discarded. For a patient with few embryos, a false discard is catastrophic arithmetic. And the population math cuts both ways: young patients have low aneuploidy rates (little to find, real discard risk), while the oldest patients often have so few blastocysts that ranking them is moot — squeezing the plausible-benefit window into a band, not a default.

Where Honest Practice Has Landed

Strip the marketing from both camps and a defensible middle emerges. Plausible-benefit candidates: patients 35–40+ with several blastocysts to rank (enough aneuploidy to find, enough embryos that discard-risk is survivable), recurrent-miscarriage and repeated-implantation-failure histories where avoiding another loss carries outsized value, and known chromosomal-translocation carriers — plus, separately and uncontroversially, PGT-M for families facing serious single-gene disease, which is a different test answering a different question. Poor candidates: patients under 35 with routine prognoses (the STAR population where benefit failed to appear), and patients with one or two blastocysts, where testing can only shrink the queue it cannot improve. The mosaicism rule: any program you use should have — and articulate — a modern policy on mosaic embryos, because "we discard everything non-euploid" is a 2015 policy running on 2026 data. Cost enters honestly too: at $3,000–6,000 US the failed-transfers-avoided arithmetic must work hard; at the $1,000–2,500 international pricing our live PGT-abroad guide covers, the same debate runs at gentler stakes — cheaper unresolved is still unresolved, but the downside of a reasonable bet shrinks. The framework question, as ever from the add-ons review: what is the live-birth evidence for patients like me — asked here with the age band and embryo count filled in, because in this debate they are the entire answer.

The Verdict

PGT-A is neither the rational-selection slam dunk its invoices imply nor the scam its angriest critics allege — it's a real technology whose benefit is narrow, age-shaped, and embryo-count-dependent, oversold at the edges by the economics of a $3,000 line item. If you're 38 with six blastocysts and two miscarriages behind you, the case for testing is genuinely strong; if you're 31 with three blastocysts and a clean history, the evidence says spend the money on the transfers themselves. Ask for the clinic's mosaic policy, run the arithmetic at your actual embryo count, and treat any program that tests everyone — or refuses to discuss testing at all — as having replaced the judgment you're paying for with a policy. The rest of the funnel this decision sits inside lives in the complete pillar.